Martin Glas

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype

Yun-Qing Li, Angela Li, Martin Glas et al. · Proceedings of the National Academy of Sciences · 2011 · 262 citations · Full text

Medicine, Cell Biology, Oncology +17

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O⁶-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Ulrich Herrlinger, Niklas Schäfer, Astrid Weyerbrock et al. · Journal of Clinical Oncology · 2016 · 197 citations

Medicine, Oncology, Pharmacotherapy +15

Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

Alexander Scholz, Patrick N. Harter, Sebastian Cremer et al. · EMBO Molecular Medicine · 2015 · 170 citations · Full text

Medicine, Neurology, Oncology +17

Anticancer Effects of Niclosamide in Human Glioblastoma

Anja Wieland, Daniel Trageser, Sabine Gogolok et al. · Clinical Cancer Research · 2013 · 161 citations

Medicine, Oncology, Pharmacology +14